Regulatory T (Treg) cells are necessary for immune system homeostasis and the prevention of autoimmune diseases. Foxp3 is specifically expressed in Treg cells and plays a key role in their differentiation and function. Foxp3
INTRODUCTION
Autoimmunity is a heterogeneous disorder, which includes at least 80 diseases and is controlled by complex genetic and environmental factors. The pathogenesis of autoimmunity is hypothesized to result from a breakdown of immune tolerance, including central and/or peripheral mechanisms, and this loss of control ultimately culminates in autoimmune diseases. 1 Whereas the immune system plays an important role in the prevention of autoimmune diseases through self-tolerance mechanisms, it must be efficient in protecting the host from insult by exogenous pathogens. In this regard, the CD4 1 T-cell represents the chief protagonist, and plays a critical role in controlling the adaptive immune system. 2 A current paradigm in immunology is that autoimmunity is elicited by an imbalance between pathogenic T cells and 
Foxp3
1 Treg cells are a specialized CD4 1 T-cell lineage that plays a central role in maintaining self-tolerance, and the dysfunction of these cells is implicated in the development of various autoimmune diseases.
5-7 CD4
1 Treg cells comprise at least two distinct subsets in the periphery, natural Treg cells (nTreg cells) produced by the thymus after recognition of high-affinity self-antigen and then move to the periphery, and induced Treg cells (iTreg cells) that are converted from conventional non-Treg cells as a consequence of peripheral exposure to antigens in the presence of transforming growth factor-beta (TGF-b) signaling. 8 The comparison of the similarities and differences between nTreg and iTreg cells has been previously reviewed. Moreover, atRA also helps preserve nTreg cell stability under inflammatory conditions. 22, 23 In this review, we summarize our understanding of the role of atRA in Treg cell biology, its related molecular mechanisms and potential clinical application for patients with autoimmune diseases and who need organ transplantation.
FOXP3 AND TREG CELL SUBSETS
Foxp3, an X chromosome linked factor that controls Treg cell development and function, is the major transcription factor for determining the fate and identity of Treg cells and is specifically expressed in Treg cells. 24, 25 Foxp3 is generally postulated to positively control Treg cell function in a binary fashion, because its expression in conventional T cells is sufficient to specify immune-suppressive activities.
7 Foxp3 is critically involved in the development and function of Treg cells, its expression appears to play a necessary role in governing Treg cell action. Treg cells also prevent autoimmune and inflammatory diseases by suppressing the potentially deleterious activities of Th cells. 4 In contrast, the downregulation of Foxp3 or Foxp3 deficiency results in multiorgan autoimmune diseases. For example, downregulation of Foxp3 in antigenexperienced Treg cells coincides with the onset of pro-inflammatory and immunoregulatory cytokine secretion, such as IL-2, IFN-c and IL-10, in these cells. 26 Recent data indicate that mature Foxp3
1 Treg cells express the highest levels of neuropilin-1 (Nrp-1), which is usually expressed on thymus-derived natural regulatory T cells. This suggests that the overwhelming majority of thymus-derived, natural Treg cells express Nrp-1.
27
Similarly, Helios provides an additional marker for the discrimination of nTreg cells from iTreg cells, although its specificity remains a concern.
28,29 Nrp-1 also identifies Foxp3 1 The adoptive transfer of nTreg cells prevents the initiation and development of autoimmune diseases in many animal models; however, the therapeutic effect of nTreg cells on autoimmune diseases remains unsatisfactory. The key reason is that inflammatory cytokines, such as IL-6, TNF-a and IL-1, may decrease Foxp3 expression and subsequently reduce the functional activity of nTreg cells.
22,23,32-36

THE STABILITY OF TREG CELL SUBSETS
Recent studies demonstrated that nTreg cells from both mouse and human are instable and dysfunctional under inflammatory conditions. 7,32,34,35,37,38 These cells not only lose their suppressive ability after encountering inflammatory environments, but they can convert into pathogenic cells that may actually accelerate the inflammatory process. 1 In addition, the repeat expansion of nTreg cells, even in the absence of pro-inflammatory cytokines, can also result in the loss of Foxp3 expression. This finding has very important implications for clinical utility because nTreg cells initially exist as a very small cell population. 26 It is therefore critical to identify approaches that maintain Foxp3 expression and Treg cell function during expansion, particularly under inflammatory conditions. Rapamycin (RAPA) may be an ideal candidate for promoting nTreg cell stability. RAPA, an mTOR kinase inhibitor, is an immunosuppressive drug that inhibits effector T-cell proliferation, migration and cytokine production, 39 and can selectively promote the expansion of suppressive human CD4
1 CD25
hi Foxp3 1 T cells isolated from healthy donors and patients with diabetes. 40, 41 It remains unclear whether RAPA selectively suppresses the expansion of non-Treg cells, thereby indirectly promoting the expansion of Foxp3 1 Treg cells. 16 Although a comparison study has shown that both RAPA and atRA had similar effects on promoting and stabilizing Treg cells during their expansion, 42 a more recent study demonstrated that atRA exhibits superior efficacy relative to RAPA for stabilizing nTreg cells under inflammatory conditions. 23 The mechanism by which atRA stabilizes nTreg cells is discussed below.
iTreg cells exhibit several characteristic differences in stability and functionality relative to nTreg cells. Whereas IL-6 can convert nTreg cells into Th17 and Th1 cells, it does not have this effect on iTreg cells. 32 Conversely, iTreg cells are stable and function effectively in an inflammatory environment.
32, 43 It is likely that TGF-b treatment reduces IL-6 receptor expression and thereby suppresses its signaling pathway. 32 Therefore, iTreg cells may play a complementary role to nTreg cells, particularly in response to self-antigens, which are not expressed in the thymus. It is possible that under inflammatory conditions, the induction of iTreg cells is suppressed and self-reactive cells develop directly into effector-memory T cells and promote autoimmune disease. Whereas TGF-b is crucial for promoting the development of iTreg cells, the presence of IL-6 interferes with the ability of TGF-b to promote this differentiation. 44 However, because iTreg cells are stable and functional under inflammatory conditions, after they have been induced, they can expand ex vivo following adoptive transfer for cell-based therapeutic treatment of patients with autoimmune inflammatory diseases.
3,45
ATRA AND TREG CELL FUNCTION atRA, the primary biologically active metabolite of vitamin A, plays vital roles in embryonic development, vision, skin Role of atRA in biology of Foxp3homeostasis and reproduction, and it also crucial for maintenance of the immune system. 46 atRA produced by dendritic cells facilitates the de novo generation of Foxp3 1 Treg cells from naive CD4
1 CD25 2 T cell populations in mice, 47, 48 but also suppress the de novo differentiation of naive CD4 1 cells into Th17 cells. 22 The effect of atRA on Treg and Th17 cells is dependent upon the RA receptor/retinoid X receptor heterodimer. 49, 50 Because the pathogenesis and development of many autoimmune diseases is affected by the imbalance between Treg and Th17 cells, the role of atRA in regulating this balance may greatly affect the progress of autoimmune diseases.
atRA appears to promote gut homing of CD4 1 T cells by inducing CCR9 and a4b7 expression, and the expression of these molecules also indicates that a given population of T cells respond to atRA. 51 An initial study showed that atRA suppresses Th1 but promotes Th2 cells. 52 Vitamin
1 iTreg cell differentiation may be different. 21 The orphan nuclear receptor, RORct, has been implicated in the gene transcription of Th17 cells. TGF-b induces high levels of RORct and further promotes Th17 cell development in the presence of IL-6. However, the addition of atRA to cultures containing TGF-b and IL-6 greatly reduces RORct expression and Th17 cell differentiation. 54 The key role played by atRA in immune tolerance is via the induction of iTreg cells. atRA plays a crucial role in maintaining gut mucosa tolerance to commensal bacteria and food antigens through the induction of both Foxp3
1 Treg cells and IL-10-producing Treg cells. 55, 56 atRA is primarily produced by CD103 1 dendritic cells in the intestine. These CD103 1 dendritic cells originate in the lamina propria, but migrate to the mesenteric lymph nodes where they drive the differentiation of gut-homing Foxp3 1 Treg cells through the production of retinoic acid from dietary vitamin A. 57 Whereas TGF-b alone is not sufficient to drive the development of human iTreg cells, the addition of atRA provides the necessary stimulus for human iTreg cell induction, demonstrating its value in clinical translation. 19 The study of molecular mechanisms demonstrated that although atRA does not significantly affect the phosphorylation levels of Smad2/3, it promotes iTreg cell induction in CD4 1 cells isolated from Smad3 knockout and Smad2 conditional knockout mice. By contrast, atRA markedly increases the activation of the ERK1/2 signaling pathway, and the resultant signaling promotes Foxp3 expression. 20 Although DNA methylation at the Foxp3 gene locus affects Foxp3 expression and maintenance by Treg cells, 58 atRA enhances the differentiation and stability of iTreg cells in the absence of any alteration of DNA methylation. Instead, atRA acts via increased histone methylation and acetylation within the promoter and conserved non-coding DNA sequence elements at the Foxp3 gene locus; 20 however, atRA can inhibit the methylation of the Foxp3 gene of nTreg in the presence of inflammatory cytokines. 23 Interestingly, atRA also helps maintain Foxp3 expression during the nTreg cell expansion process. 22 This has recently been extended to human nTreg cells. 23 Compared with RAPA, the effect of atRA on stabilizing Foxp3 expression and Treg cell function is superior under inflammatory conditions. 23 atRA promotes the expression of cytotoxic T lymphocyte antigen 4(CTLA-4), a cell-surface receptor typically expressed by Treg cells on the majority of TGF-b-generated Foxp3 1 cells. The B7/CTLA-4 signal is crucial for the development and function of iTreg cells. 59 atRA also enhances the expression of surface TGF-b on nTreg cells, 23 which is another possible mechanism for nTreg cell stabilization. In addition, atRA also downregulates IL-6R expression and IL-6R signaling on nTreg cells, rendering nTreg cells resistant to the pro-inflammatory cytokine, IL-6, which is usually elevated in autoimmune diseases. 60 The key role atRA plays in promoting iTreg cells development and nTreg cells stabilization is summarized in Figure 1 . These characteristics highly suggest that atRA-treated nTreg cells from patients with rheumatoid arthritis and other autoimmune diseases could potentially be used to control disease development and even cure patients. The combination of atRA and TGF-b also provides another approach to develop Treg cell therapy for patients with autoimmune diseases and the prevention of allograft reject in patients with organ transplantation. Role of atRA in biology of Foxp3
CONCLUSIONS
